Giving voice to people with a misunderstood disease

Giving voice to people with a misunderstood disease
mihai_novartis

/by
Water project revives rural community in India

Water project revives rural community in India
mihai_novartis

/by
Water project revives rural community in India

Water project revives rural community in India
mihai_novartis

/by
A partnership against epilepsy

A partnership against epilepsy
tavasat1

/by
A partnership against epilepsy

A partnership against epilepsy
tavasat1

/by
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
arcticnovartis

  • In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs.
/by
Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024

Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024
imberje1

/by
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia

Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
arcticnovartis

MEDIA & INVESTOR RELEASE

Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia

Ad hoc announcement pursuant to Art. 53

/by
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis

Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
arcticnovartis

  • FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond
  • New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrally located in the US to maximize access for patients and treatment centers
/by
Novartis at the J.P. Morgan Healthcare Conference 2024

Novartis at the J.P. Morgan Healthcare Conference 2024
angilma1

/by